Inactivation of LEF1 in T-cell acute lymphoblastic leukemia.

PubWeight™: 1.40‹?› | Rank: Top 5%

🔗 View Article (PMC 2854430)

Published in Blood on February 01, 2010

Authors

Alejandro Gutierrez1, Takaomi Sanda, Wenxue Ma, Jianhua Zhang, Ruta Grebliunaite, Suzanne Dahlberg, Donna Neuberg, Alexei Protopopov, Stuart S Winter, Richard S Larson, Michael J Borowitz, Lewis B Silverman, Lynda Chin, Stephen P Hunger, Catriona Jamieson, Stephen E Sallan, A Thomas Look

Author Affiliations

1: Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Associated clinical trials:

Treatment of Acute Lymphoblastic Leukemia in Children | NCT00165178

Articles citing this

The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest (2012) 3.09

The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy. Immunity (2012) 2.15

Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood (2013) 1.74

Cyclin C is a haploinsufficient tumour suppressor. Nat Cell Biol (2014) 1.68

The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood (2011) 1.45

Myc roles in hematopoiesis and leukemia. Genes Cancer (2010) 1.23

Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification. Haematologica (2012) 1.20

MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context. Haematologica (2010) 1.16

Mutational spectrum of adult T-ALL. Oncotarget (2015) 1.09

The nuclear effector of Wnt-signaling, Tcf1, functions as a T-cell-specific tumor suppressor for development of lymphomas. PLoS Biol (2012) 1.06

Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia. Haematologica (2011) 1.06

The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer (2016) 1.00

Characterization of LEF1 High Expression and Novel Mutations in Adult Acute Lymphoblastic Leukemia. PLoS One (2015) 0.96

The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther Adv Hematol (2013) 0.94

Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. Haematologica (2015) 0.89

Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments. Curr Hematol Malig Rep (2012) 0.89

Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians. Eur J Pediatr (2011) 0.89

NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One (2012) 0.87

Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. Leukemia (2014) 0.85

Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia. Leuk Res (2012) 0.85

Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia. Oncotarget (2015) 0.84

Modulation of activation-associated host cell gene expression by the apicomplexan parasite Theileria annulata. Cell Microbiol (2012) 0.82

Identification of DNA-dependent protein kinase catalytic subunit as a novel interaction partner of lymphocyte enhancer factor 1. Med Mol Morphol (2013) 0.80

Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations. Oncotarget (2016) 0.79

Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A. J Hematol Oncol (2015) 0.78

Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison. Front Oncol (2014) 0.76

Prognostic significance of lymphoid enhancer-binding factor-1 expression in egyptian adult B-acute lymphocytic leukemia patients. Turk J Haematol (2015) 0.76

β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1. Leukemia (2016) 0.76

The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet (2017) 0.75

Prognostification of ALL by Cytogenetics. Indian J Hematol Blood Transfus (2014) 0.75

Identifying new targets in leukemogenesis using computational approaches. Saudi J Biol Sci (2015) 0.75

LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma. Oncotarget (2016) 0.75

Gene expression network analyses in response to air pollution exposures in the trucking industry. Environ Health (2016) 0.75

Novel insights on TLX1 function in T-ALL pave the way towards differentiation therapy. Haematologica (2012) 0.75

Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci (2017) 0.75

Articles cited by this

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46

PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59

GenePattern 2.0. Nat Genet (2006) 29.07

Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84

A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64

Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev (1994) 6.07

Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65

Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet (2001) 5.09

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89

FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59

Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia (1995) 4.04

The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 4.04

Interaction between Wnt and TGF-beta signalling pathways during formation of Spemann's organizer. Nature (2000) 3.35

Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell (2008) 3.15

HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood (2005) 3.09

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02

All Tcf HMG box transcription factors interact with Groucho-related co-repressors. Nucleic Acids Res (2001) 2.98

Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol (2003) 2.88

Expression of DeltaNLef1 in mouse epidermis results in differentiation of hair follicles into squamous epidermal cysts and formation of skin tumours. Development (2002) 2.79

Redundant regulation of T cell differentiation and TCRalpha gene expression by the transcription factors LEF-1 and TCF-1. Immunity (1998) 2.57

New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. J Exp Med (2005) 2.44

Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood (2003) 2.35

Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med (2004) 2.05

TCF transcription factors, mediators of Wnt-signaling in development and cancer. Dev Biol (2002) 1.93

New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening. Sci Signal (2008) 1.88

TGFbeta3 inhibits E-cadherin gene expression in palate medial-edge epithelial cells through a Smad2-Smad4-LEF1 transcription complex. J Cell Sci (2007) 1.73

The human LEF-1 gene contains a promoter preferentially active in lymphocytes and encodes multiple isoforms derived from alternative splicing. Nucleic Acids Res (2000) 1.50

Beta-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation. Blood (2007) 1.48

The notch intracellular domain can function as a coactivator for LEF-1. Mol Cell Biol (2001) 1.45

A genome-wide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. Mol Cell Biol (2008) 1.42

Human sebaceous tumors harbor inactivating mutations in LEF1. Nat Med (2006) 1.40

Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med (2007) 1.37

A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med (2008) 1.34

Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2007) 1.19

Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol (2004) 1.17

Transcriptional control of t lymphocyte differentiation. Stem Cells (2001) 1.12

HOXA cluster deregulation in T-ALL associated with both a TCRD-HOXA and a CALM-AF10 chromosomal translocation. Leukemia (2006) 0.91

Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia (2007) 0.87

Articles by these authors

Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19

A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52

International network of cancer genome projects. Nature (2010) 20.35

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84

Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20

The genomic complexity of primary human prostate cancer. Nature (2011) 14.06

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79

A landscape of driver mutations in melanoma. Cell (2012) 12.61

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54

Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89

Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24

FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94

Acute lymphoblastic leukaemia. Lancet (2008) 8.54

Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99

Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89

Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80

NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 6.80

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64

High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52

Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36

Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med (2003) 6.07

Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71

Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65

A genetic screen for candidate tumor suppressors identifies REST. Cell (2005) 5.61

A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature (2009) 5.55

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood (2008) 5.49

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37

H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23

DNA breaks and chromosome pulverization from errors in mitosis. Nature (2012) 5.19

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00

JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93

Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92

Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A (2012) 4.85

Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80

Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71

Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68

FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood (2003) 4.43

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41

Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature (2010) 4.36

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood (2010) 4.35

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20

tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A (2005) 4.15

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol (2003) 4.07

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (2011) 4.06

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood (2010) 4.00

An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (2007) 4.00

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood (2006) 3.91

Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer (2006) 3.89

Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84

Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell (2011) 3.81

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75

High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75

Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell (2005) 3.73

Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71